Obsidian Therapeutics, Inc. (OBX) Stock Price & Analysis
Obsidian Therapeutics, Inc. (OBX) closed at USD 12.2 on Thursday, October 15, 2026, down 0.16% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 12.22; the Oct 15, 2026 session ranged USD 12.06–12.67 on volume of 240,337 shares. Market capitalization is $753.63M, with a 52-week range of USD 11.79–49.97 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OBX.md
Key facts (OBX)
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 39 (range 32–43).
- Total return with dividends: 1Y -30.3% vs S&P 500 +18.1%; 5Y -21.9% vs S&P 500 +85.1%.
Analysts (OBX)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 39 (low 32, high 43).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | Leerink Partners | Initiated | Outperform | $32 |
| 2026-09-09 | William Blair | Initiated | Outperform | |
| 2026-08-18 | LifeSci Capital | Initiated | Outperform | $43 |
| 2026-08-05 | Piper Sandler | Initiated | Overweight | $42 |
Total return (dividends reinvested) (OBX)
| 1Y (from 2026-07-27) | 5Y (from 2026-07-27) | |
|---|---|---|
| Total return | -30.3% | -21.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 188.4% | 178.7% |
| Max drawdown | -65.7% (Aug 2026→Oct 2026) | -55.6% (Aug 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 12.2 |
|---|---|
| Change | ▼ 0.16% (down) |
| Previous Close | USD 12.22 |
| Open | USD 12.31 |
| Day Range | USD 12.06 – 12.67 |
| 52-Week Range | USD 11.79 – 49.97 |
| Volume | 240,337 shares |
| Market Cap | $753.63M |
| Exchange | NCM |
Technical Analysis (OBX)
Nexqual's technical model rates OBX "SELL" based on 1 bullish and 5 bearish signals across 58 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.65 (neutral) |
| vs SMA50 | Below (USD 17.6) |
| MACD | -1.5 (negative) |
Analyst Ratings (OBX)
Wall Street analysts rate OBX "Buy" based on 5 analysts, with a mean price target of USD 39 (range USD 32–43), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 39 |
| High Target | USD 43 |
| Low Target | USD 32 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (OBX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.19 vs est -1.64 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (OBX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.1 |
| Current Ratio | 2.3 |
| Total Cash | $34.45M |
| Total Debt | $2.91M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (OBX)
Nexqual rates Obsidian Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $34M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$92M (TTM) |
| Efficiency | Mixed — No data |
Ownership (OBX)
| Insider Ownership | +0.81% |
|---|---|
| Institutional Ownership | +35.44% |
| Shares Outstanding | 61.77M |
| Float | 48.85M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (OBX)
Obsidian Therapeutics, Inc. is led by Madan Jagasia M.D., M.S. (age 55), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| President, CEO & Director | Madan Jagasia M.D., M.S. (age 55) |
|---|---|
| Executive Chairman of the Board | Maria Fardis (age 57) |
| Chief Financial Officer | Julie B. Feder (age 54) |
| Vice President of Corporate Development & Investor Relations | Caroline Code |
| Secretary & Director | Peter Barrett (age 72) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt